Visfatin levels in pulmonary disease: a systematic review and meta-analysis.

IF 3.1 3区医学 Q1 MEDICINE, GENERAL & INTERNAL

Frontiers in Medicine Pub Date : 2025-09-19 eCollection Date: 2025-01-01 DOI:10.3389/fmed.2025.1541595

Muhammad Islampanah, Reza Hossein Zadeh, Abolfazl Akbari, Hamed Ghoshouni, Mehrnush Saghab Torbati, Javad Ghasemi, Raheleh Ganjali, Masoumeh Sadeghi, Mahnaz Mozdourian

{"title":"Visfatin levels in pulmonary disease: a systematic review and meta-analysis.","authors":"Muhammad Islampanah, Reza Hossein Zadeh, Abolfazl Akbari, Hamed Ghoshouni, Mehrnush Saghab Torbati, Javad Ghasemi, Raheleh Ganjali, Masoumeh Sadeghi, Mahnaz Mozdourian","doi":"10.3389/fmed.2025.1541595","DOIUrl":null,"url":null,"abstract":"Background: Visfatin has been demonstrated to have pro-inflammatory effects and is involved in several respiratory disorders, including chronic obstructive pulmonary disease (COPD), asthma, and pneumonia. However, there are some inconsistent findings. This study aimed to assess the association between serum visfatin levels and COPD, pneumonia, asthma, interstitial lung disease (ILD), and bronchiectasis.Methods: A systematic review and meta-analysis were conducted following the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. PubMed, Scopus, and Web of Science databases were searched. Studies including a healthy control group and measuring serum visfatin in patients with COPD, asthma, pneumonia, bronchiectasis, or ILD were included. Stata 17 was used for data analysis.Results: Fourteen studies were included. None of them were on bronchiectasis. The analysis showed no significant difference between the COPD group and healthy controls in terms of serum visfatin levels (effect size = -0.02, %95CI: [-0.74, 0.69], p = 0.95). Similarly, analysis of visfatin levels in asthma studies showed no significant difference between patients and healthy controls (effect size = -1.51, %95CI: [-6.82, 3.79], p = 0.58). However, Serum visfatin levels were significantly higher in pneumonia patients compared to healthy controls (effect size = 1.93, %95CI: [0.91, 2.95], p < 0.01).Conclusion: Circulating levels of visfatin may be associated with pneumonia, but not COPD or asthma. However, there are still few studies on the levels of visfatin in COPD, asthma, and pneumonia patients, and there is a need for further investigation.Systematic review registration: PROSPERO, identifier (CRD42023441144).","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1541595"},"PeriodicalIF":3.1000,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12491028/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2025.1541595","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Visfatin has been demonstrated to have pro-inflammatory effects and is involved in several respiratory disorders, including chronic obstructive pulmonary disease (COPD), asthma, and pneumonia. However, there are some inconsistent findings. This study aimed to assess the association between serum visfatin levels and COPD, pneumonia, asthma, interstitial lung disease (ILD), and bronchiectasis.

Methods: A systematic review and meta-analysis were conducted following the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. PubMed, Scopus, and Web of Science databases were searched. Studies including a healthy control group and measuring serum visfatin in patients with COPD, asthma, pneumonia, bronchiectasis, or ILD were included. Stata 17 was used for data analysis.

Results: Fourteen studies were included. None of them were on bronchiectasis. The analysis showed no significant difference between the COPD group and healthy controls in terms of serum visfatin levels (effect size = -0.02, %95CI: [-0.74, 0.69], p = 0.95). Similarly, analysis of visfatin levels in asthma studies showed no significant difference between patients and healthy controls (effect size = -1.51, %95CI: [-6.82, 3.79], p = 0.58). However, Serum visfatin levels were significantly higher in pneumonia patients compared to healthy controls (effect size = 1.93, %95CI: [0.91, 2.95], p < 0.01).

Conclusion: Circulating levels of visfatin may be associated with pneumonia, but not COPD or asthma. However, there are still few studies on the levels of visfatin in COPD, asthma, and pneumonia patients, and there is a need for further investigation.

Systematic review registration: PROSPERO, identifier (CRD42023441144).

查看原文本刊更多论文

肺疾病的内脏素水平：一项系统综述和荟萃分析。

背景：Visfatin已被证明具有促炎作用，并参与多种呼吸系统疾病，包括慢性阻塞性肺疾病（COPD）、哮喘和肺炎。然而，有一些不一致的发现。本研究旨在评估血清visfatin水平与COPD、肺炎、哮喘、间质性肺疾病（ILD）和支气管扩张之间的关系。方法：根据流行病学观察性研究（MOOSE）指南的荟萃分析进行系统评价和荟萃分析。检索了PubMed、Scopus和Web of Science数据库。研究包括健康对照组和COPD、哮喘、肺炎、支气管扩张或ILD患者血清visfatin的测定。使用Stata 17进行数据分析。结果：纳入14项研究。没有一例支气管扩张。分析显示，COPD组与健康对照组血清visfatin水平无显著差异（效应值 = -0.02,%95CI: [-0.74, 0.69], p = 0.95）。同样，哮喘研究中visfatin水平的分析显示，患者与健康对照组之间无显著差异（效应量 = -1.51,%95CI: [-6.82, 3.79], p = 0.58）。然而，肺炎患者血清内脂素水平明显高于健康对照组(效应值 = 1.93,%95CI: [0.91, 2.95]， p结论：循环内脂素水平可能与肺炎有关，但与COPD或哮喘无关。然而，关于慢性阻塞性肺病、哮喘和肺炎患者visfatin水平的研究仍然很少，需要进一步研究。系统评价注册：PROSPERO，标识符（CRD42023441144）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Medicine Medicine-General Medicine

CiteScore

5.10

自引率

5.10%

发文量

3710

审稿时长

12 weeks

期刊介绍： Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate - the use of patient-reported outcomes under real world conditions - the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines - the scientific bases for guidelines and decisions from regulatory authorities - access to medicinal products and medical devices worldwide - addressing the grand health challenges around the world